Available Now!

Catalog number
Product type
96 Tests (12x8 breakable strip wells)
Standard range
15-400 U/mL
Sample volume
50 µl/well
Storage and Stability
Product should be stored at 2-8 °C. 
Potential biohazardous materials:
The calibrator and controls contain human source components, which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents.  However, as there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent, these reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984
This test kit is designed for Research Use Only.
Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
The components in this kit are intended for use as an integral unit.  The components of different lots should not be mixed.
It is recommended that serum samples be run in duplicate.
Optimal results will be obtained by strict adherence to this protocol.  Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential.  Any deviation from this may yield invalid data.
  • all, E., Methods in Enzymology, Volume 70, Van Vunakis, H.  and Langone, J. J. (eds.), Academic Press, New York, 419- 492   (1980).
  • tila, M., Ruoslahti, E. and Engvall, E., J. lmmunol. Methods, 42, 11-15 (1981).
  • Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. Ca125 in gynecological pathology a review. Eur J Obstet Gynecol 1993;49:115-124.
  • Saksela F. Prognostic markers in epithelial ovarian cancer. Intl J Gynecol Pathol 1993;12:156-161.
  • Farghaly SA. Tumor markers in gynecologic cancer. Gynecol & Obstet Invest 1992;34:65-72.
  • Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology. Acta Obstet Gynecol Scand Sup 1992;155:85-93.
  • McGowan L. Pathology of the ovary. Curr Opin on Obstet Gynecol 1991;3:580-586.
  • Niloff JM. Ovarian malignancy. Curr Opin on Obstet Gynecol 1991;3:66-72.
  • Olt G, Berchuck A, Bast RC. The role of tumor markers in gynecologic oncology. Obstet Gynecol Survey 1990;45-:570-577.
  • Diez M, Cerdan FJ, Ortega MD, Torres A, Picardo A, Balibrea JL. Evaluation of serum CA125 as a tumor marker in non-small cell lung cancer. Cancer 1991;67:150-154.
  • Niloff JM, Klug TL, Schaetzl E. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. AM J. Obstet Gynecol 1984; 148:1057